Evelo Biosciences Sees Unusually High Options Volume (NASDAQ:EVLO)

Evelo Biosciences, Inc. (NASDAQ:EVLO) was the target of some unusual options trading on Wednesday. Investors bought 1,885 put options on the stock. This represents an increase of 1,101% compared to the average volume of 157 put options.

Evelo Biosciences Price Performance

Shares of Evelo Biosciences stock opened at $0.05 on Thursday. The stock’s 50-day simple moving average is $0.05 and its 200-day simple moving average is $0.72. Evelo Biosciences has a 52 week low of $0.03 and a 52 week high of $13.93. The company has a market capitalization of $949,000.00, a price-to-earnings ratio of 0.00 and a beta of 2.03.

Hedge Funds Weigh In On Evelo Biosciences

Large investors have recently made changes to their positions in the business. FMR LLC lifted its position in shares of Evelo Biosciences by 1,835.1% in the third quarter. FMR LLC now owns 2,446,390 shares of the company’s stock worth $9,590,000 after buying an additional 2,319,965 shares in the last quarter. Susquehanna International Group LLP lifted its position in shares of Evelo Biosciences by 549.9% in the fourth quarter. Susquehanna International Group LLP now owns 146,059 shares of the company’s stock worth $235,000 after buying an additional 123,586 shares in the last quarter. Trustees of Columbia University in the City of New York purchased a new stake in shares of Evelo Biosciences in the fourth quarter worth about $183,000. Citigroup Inc. lifted its position in shares of Evelo Biosciences by 1,522.6% in the fourth quarter. Citigroup Inc. now owns 99,625 shares of the company’s stock worth $160,000 after buying an additional 93,485 shares in the last quarter. Finally, Morgan Stanley lifted its position in shares of Evelo Biosciences by 22.6% in the fourth quarter. Morgan Stanley now owns 78,892 shares of the company’s stock worth $127,000 after buying an additional 14,567 shares in the last quarter. 0.31% of the stock is currently owned by hedge funds and other institutional investors.

Evelo Biosciences Company Profile

Evelo Biosciences, Inc, a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis.